Vasostenone, 20 µg/ml concentrate 1 ml

Microcirculatory disorders Treatment of chronic peripheral arterial obliterative diseases of stages III and IV in adults with vasodilator effect if the procedure cannot be performed, or if such procedure was not successful.

Active ingredient

Alprostadil

Interaction

When treating with the drug, the effect of hypotensive drugs, vasodilators and antianginal drugs may increase. When concomitant use of these drugs with Alprostadil and other vasodilators, careful monitoring of the cardiovascular system, including monitoring of blood pressure, is required.

Directions for use

Vasostenone is intended for intra-arterial or intravenous administration in the form of a solution. It is recommended to use an automatic syringe or an infusion pump and a catheter for infusion therapy. The dosage diagram shows daily doses calculated for patients with normal renal function and body weight of 70 kg.

Special Instructions

Patients in the risk group should be treated with caution, closely monitoring the patient during administration of each dose. Patients who are prone to heart failure due to their age and patients with coronary heart disease should be under observation in the hospital during treatment and for one day after discontinuation of the drug therapy. The drug should also be administered with caution in case of arterial hypotension.

Contraindications

Hypersensitivity to alprostadil or other drug components; cardiac dysfunction: New York Heart Association (NYHA) class III or IV decompensated heart failure due to previous ineffective treatment;

Side effects

Side effects are classified by frequency as follows: very common (≥ 1/10), common (≥ 1/100, < 1/10), infrequent (≥ 1/1000, < 1/100), rare (≥ 1/10000, < 1/1000), very rare (< 1/10000), unknown frequency (cannot be estimated from available data).

Overdose

Symptoms . Overdose of the drug may result in decreased blood pressure and reflex tachycardia due to the effect of vasodilation.

Similarities

Caverject